Analytische Chemie
Filtern
Dokumenttyp
- Zeitschriftenartikel (3)
- Vortrag (1)
- Sonstiges (1)
Sprache
- Englisch (5)
Schlagworte
- Diagnostics (5) (entfernen)
Organisationseinheit der BAM
Eingeladener Vortrag
- nein (1)
Multiplexed bead-based array formats play an increasingly important role in analytical laboratories. Due to the high surface-to-volume ratio, fast reaction kinetics and modular assay design, these sensor formats are applied in clinical diagnostic, drug development and classical biosensors with great success.
As the spherical platform, researchers utilize micron sized particles made from polymeric or silica material. Such beads are commercially available from vendors such as BD or Luminex. However, we have encountered several problematic issues which accompany these platforms: first, bigger sized beads, which are required for particle handling reasons, are difficult to prepare with high monodispersity - a key requirement for cytometric application. Second, plain beads, made from either polymer or silica, have each several disadvantages such as inferior scattering properties in case of silica or limited flexibility for coupling strategies in the case of latex beads.
In order to overcome this problem, we have developed a versatile core-shell (CS) platform which consists of a polymeric core with a structurally controlled silica shell. In our approach, the core building block can be easily prepared with high yields and high monodispersity in a dispersion polymerization from approximately 500 nm to 1.3 µm. Then, silica is coated in a classical sol-gel process to protect the core with a stable yet modifiable surface (see SEM image in Figure 1, platform). Here, we combine ideal scattering properties and easy preparation of the polymeric core with the chemical flexibility of a silica surface. Moreover, the additional shell domain adds density to the composite, which makes particle handling feasible also for nanometer sized beads.
In this contribution we present proof-of-principle results of competitive immunoassays with fluorescence detection using our CS beads – each performed in mix-and-read fashion without washing steps. All sizes are applicable in cytometric read-out which and can be used for size encoding (see Set 1 to 3 in Figure 1, size encoding). However, further multiplexing for a set of at least 20 parameters can be achieved by swelling hydrophobic dyes into the core. To the same time, precise tuning of the surface with mixed silane layers allowed us to improve the selectivity towards small molecules in competitive immunoassays significantly (see example in Figure 1, Application). We believe that our platform allows researchers to gain access to superior assay performance in combination with a low-threshold approach for the synthesis of the spherical platform.
Development of theranostic concepts that include inductively coupled plasma mass spectrometry (ICP-MS) and laser ablation ICP-MS (LA-ICP-MS) imaging can be hindered by the lack of a direct comparison to more standardly used methods for in vitro and in vivo evaluation; e.g. fluorescence or nuclear medicine. In this study a bimodal (or rather, hybrid) tracer that contains both a fluorescent dye and a chelate was used to evaluate the existence of a direct link between mass spectrometry (MS) and in vitro and in vivo molecular imaging findings using fluorescence and radioisotopes. At the same time, the hybrid label was used to determine whether the use of a single isotope label would allow for MS-based diagnostics.
Online immunocapture ICP‑MS for the determination of the metalloprotein ceruloplasmin in human serum
(2018)
The human copper-protein ceruloplasmin (Cp) is the major copper-containing protein in the human body. The accurate determination of Cp is mandatory for the reliable diagnosis of several diseases. However, the analysis of Cp has proven to be difficult. The aim of our work was a proof of concept for the determination of a metalloprotein-based on online immunocapture ICP-MS. The immuno-affinity step is responsible for the enrichment and isolation of the analyte from serum, whereas the compound-independent quantitation with ICP-MS delivers the sensitivity,
precision, and large dynamic range. Off-line ELISA (enzyme-linked immunosorbent assay) was used in parallel to confirm the elution profile of the analyte with a structure-selective method. The total protein elution was observed with the 32S mass trace. The ICP-MS signals were normalized on a 59Co signal. The human copper-protein Cp could be selectively determined. This was shown with pure Cp and with a sample of human serum. The good correlation with off-line ELISA shows that Cp could be captured and eluted selectively from the anti-Cp affinity column and subsequently determined by the copper signal of ICP-MS.
Thousands of antibodies for diagnostic and other analytical purposes are on the market. However, it is often difficult to identify duplicates, reagent changes, and to assign the correct original publications to an antibody. This slows down scientific progress and might even be a cause of irreproducible research and a waste of resources. Recently, activities were started to suggest the sole use of recombinant antibodies in combination with the open communication of their sequence. In this case, such uncertainties should be eliminated. Unfortunately, this approach seems to be rather a long-term vision since the development and manufacturing of recombinant antibodies remain quite expensive in the foreseeable future. Nearly all commercial antibody suppliers also may be reluctant to publish the sequence of their antibodies, since they fear counterfeiting. De novo sequencing of antibodies is also not feasible today for a reagent user without access to the hybridoma clone. Nevertheless, it seems to be crucial for any scientist to have the opportunity to identify an antibody undoubtedly to guarantee the traceability of any research activity using antibodies from a third party as a tool. For this purpose, we developed a method for the identification of antibodies based on a MALDI-TOF MS fingerprint. To circumvent lengthy denaturation, reduction, alkylation, and enzymatic digestion steps, the fragmentation was performed with a simple formic acid hydrolysis step. Eighty-nine unknown monoclonal antibodies were used for this study to examine the feasibility of this approach. Although the molecular assignment of peaks was rarely possible, antibodies could be easily recognized in a blinded test, simply from their mass-spectral fingerprint. A general protocol is given, which could be used without any optimization to generate fingerprints for a database. We want to propose that, in most scientific projects relying critically on antibody reagents, such a fingerprint should be established to prove and document the identity of the used antibodies, as well as to assign a specific reagent to a datasheet of a commercial supplier, public database record, or antibody ID.
Thousands of antibodies for diagnostic and other analytical purposes are on the market. However, it is often difficult to identify duplicates, reagent changes, and to assign the correct original publications to an antibody. This slows down scientific progress and might even be a cause of irreproducible research and a waste of resources. Recently, activities were started to suggest the sole use of recombinant antibodies in combination with the open communication of their sequence. In this case, such uncertainties should be eliminated. Unfortunately, this approach seems to be rather a long-term vision since the development and manufacturing of recombinant antibodies
remain quite expensive in the foreseeable future. Also, nearly all commercial antibody suppliers may be reluctant to publish the sequence of their antibodies, since they fear counterfeiting. De-novo sequencing of antibodies is also not feasible today for a reagent user without access to the hybridoma clone. Nevertheless, it seems to be crucial for any scientist to have the opportunity to identify an antibody undoubtedly to guarantee the traceability of any research activity using antibodies from a third party as a tool. For this purpose, we developed a method for the identification of antibodies based on a MALDI-TOF-MS fingerprint. To circumvent lengthy denaturation, reduction, alkylation, and enzymatic digestion steps, the fragmentation was performed with a simple formic acid hydrolysis step. Eighty-nine unknown monoclonal antibodies were used for this study to examine the feasibility of this approach. Although the molecular assignment of peaks was rarely possible, antibodies could be easily recognized in a blinded test, simply from their mass-spectral fingerprint. A general protocol is given, which could be used without any optimization to generate fingerprints for a database. We want to propose that in most scientific projects relying critically on antibody reagents, such a fingerprint should be established to prove and document the identity of the used antibodies and to assign a specific reagent to a datasheet of a commercial supplier, a public database record or an antibody ID.